Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and ...

Patient BMI did not affect treatment outcomes across several efficacy measures among patients with AD who were treated with JAK inhibitors.

In a challenge brought by competitor Sanofi, BBB National Programs’ National Advertising Division found certain Galderma ...

The partnership will focus on educating the eczema and sensitive skin communities about the brand and how it can be utilized ...

Trump has called its initiative an “historic” step in drug pricing policy. But the lack of critical details makes it hard to ...

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, ...

This approval follows the recent FDA approval of ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor, as a treatment ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) shares gained 1.5% in premarket trading Monday after the U.S. Food and Drug ...

Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock gained 1.5% in Monday’s premarket trading after the U.S. Food and Drug Administration approved its ZORYVE cream for treating mild to ...

Pfizer delivered strong 2Q25 results with double-digit revenue growth and margin expansion. Click here to read why PFE stock ...

Last month, Nektar Therapeutics presented results for its experimental eczema treatment. The eczema treatment Nektar ...

True or False: Early data from a randomized trial showed that acetaminophen (Tylenol) led to a greater risk of eczema in ...